2025
Early Release - Mycobacterium nebraskense Isolated from Patients in Connecticut and Oregon, USA - Volume 31, Number 3—March 2025 - Emerging Infectious Diseases journal - CDC
Metersky M, Losier A, Fraulino D, Warnock T, Varley C, Le A, Winthrop K, McArdle J, Shakir S, Khare R. Early Release - Mycobacterium nebraskense Isolated from Patients in Connecticut and Oregon, USA - Volume 31, Number 3—March 2025 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2025, 31: 507-515. PMID: 40023800, PMCID: PMC11878316, DOI: 10.3201/eid3103.240608.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnti-Bacterial AgentsConnecticutFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium Infections, NontuberculousNontuberculous MycobacteriaOregonConceptsNontuberculous mycobacterial pulmonary diseaseMycobacterial pulmonary diseaseAmerican Thoracic Society/Infectious Diseases Society of America criteriaAntimicrobial drug susceptibility testingPulmonary diseaseDrug susceptibility testingRefractory to treatmentClinically significant causeClarithromycin susceptibilitySusceptibility testingConnecticut patientsRespiratory secretionsPatientsNo symptomsOptimum treatmentSignificant causeInfectionHuman casesDiseaseTreatmentCDCClarithromycinCasesClinicM. nebraskenseCharacterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates
Maher J, Huband M, Lindley J, Rhomberg P, Aronin S, Puttagunta S, Castanheira M. Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates. Microbiology Spectrum 2025, 13: e01898-24. PMID: 39907459, PMCID: PMC11878024, DOI: 10.1128/spectrum.01898-24.Peer-Reviewed Original ResearchConceptsUncomplicated urinary tract infectionsPost-antibiotic effectIntra-abdominal infectionsTreatment of urinary tractTime-kill testsMultidrug-resistant pathogensBaseline MICPenem antibioticUrinary tractPAE effectsClinical developmentBroth microdilution susceptibility testingPhase 3 clinical trialsKlebsiella pneumoniae isolatesOral dosing regimenUrinary tract infectionMicrodilution susceptibility testingPAE-SMETime-kill assayTime-kill kineticsStudy evaluated <i>inMg/500 mgAmoxicillin-clavulanateTract infectionsSusceptibility testing
2024
Durlobactam in combination with β-lactams to combat Mycobacterium abscessus
Shin E, Dousa K, Taracila M, Bethel C, Nantongo M, Nguyen D, Akusobi C, Kurz S, Plummer M, Daley C, Holland S, Rubin E, Bulitta J, Boom W, Kreiswirth B, Bonomo R. Durlobactam in combination with β-lactams to combat Mycobacterium abscessus. Antimicrobial Agents And Chemotherapy 2024, 69: e01174-24. PMID: 39714147, PMCID: PMC11823594, DOI: 10.1128/aac.01174-24.Peer-Reviewed Original ResearchTargeting Pseudomonas aeruginosa biofilm with an evolutionary trained bacteriophage cocktail exploiting phage resistance trade-offs
Kunisch F, Campobasso C, Wagemans J, Yildirim S, Chan B, Schaudinn C, Lavigne R, Turner P, Raschke M, Trampuz A, Gonzalez Moreno M. Targeting Pseudomonas aeruginosa biofilm with an evolutionary trained bacteriophage cocktail exploiting phage resistance trade-offs. Nature Communications 2024, 15: 8572. PMID: 39362854, PMCID: PMC11450229, DOI: 10.1038/s41467-024-52595-w.Peer-Reviewed Original ResearchConceptsResistance trade-offBacteriophage host rangeViruses of bacteriaHuman microbial infectionsMultidrug-resistant bacterial infectionsTwo-phage cocktailMultidrug-resistant Pseudomonas aeruginosa strainsLytic bacteriophagesBiofilm-associatedEvolution assaysPlanktonic culturesBacteriophage cocktailHost rangeBacteriophageHost spectrumBacteriophage therapyCocktail designCombat biofilmsTreated bacteriaMicrobial infectionsAntimicrobial efficacyBacterial suppressionPolymerase chain reactionBacterial infectionsClinical outcomesPotential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
McQuaid C, Ryckman T, Menzies N, White R, Cohen T, Kendall E. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1571-1579. PMID: 39043388, PMCID: PMC11286077, DOI: 10.3201/eid3008.240541.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMycobacterium tuberculosisRifampinTreatment OutcomeTuberculosisTuberculosis, Multidrug-ResistantConceptsResistance to novel drugsStandard of careAntimicrobial resistanceIncreasing prevalence of antimicrobial resistancePrevalence of antimicrobial resistanceIncreased prevalenceDrug susceptibility testingCompare treatment outcomesFirst-line drugsNovel drugsTB patient cohortTreatment regimensPatient cohortNew tuberculosisRegimensTreatment outcomesComponent drugsDrugCohortTuberculosisCDCUniversal useClinicCarePrevalenceSynergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus
Dousa K, Shin E, Kurz S, Plummer M, Nantongo M, Bethel C, Taracila M, Nguyen D, Kreiswith B, Daley C, Remy K, Holland S, Bonomo R. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. MBio 2024, 15: e00609-24. PMID: 38742824, PMCID: PMC11237399, DOI: 10.1128/mbio.00609-24.Peer-Reviewed Original ResearchConceptsD,D-carboxypeptidaseMinimum inhibitory concentrationB-lactamPenicillin-binding-proteinCell wall synthesisL,D-transpeptidasesResistance to common antibioticsLowest minimum inhibitory concentrationWall synthesisCystic fibrosisD-carboxypeptidaseMass spectrometry analysisB-lactamaseThioester bondRate of treatment failureCell-based assaysMultiple antibioticsB-lactam ringsCommon antibioticsD-transpeptidasesB-lactamase inhibitorsCysteine residuesTime-kill studiesStructural lung diseaseMultidrug-resistant tuberculosisDurlobactam, a Diazabicyclooctane β‑Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis
Nantongo M, Nguyen D, Bethel C, Taracila M, Li Q, Dousa K, Shin E, Kurz S, Nguyen L, Kreiswirth B, Boom W, Plummer M, Bonomo R. Durlobactam, a Diazabicyclooctane β‑Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis. ACS Infectious Diseases 2024, 10: 1767-1779. PMID: 38619138, DOI: 10.1021/acsinfecdis.4c00119.Peer-Reviewed Original ResearchConceptsESI-MSElectrospray ionization mass spectrometryIonization mass spectrometryB-lactamase inhibitorsAcyl-enzyme complexMycobacterial cell wall synthesisMolecular dockingMass spectrometryActive siteInhibit BlaCPeptidoglycan transpeptidaseDiazabicyclooctaneSynthesisAntibiotic susceptibility testingCell wall synthesisInhibition kineticsDrug targetsB-lactamaseDurlobactamSusceptibility testingComplexDockingSpectrometryWall synthesisPeptidoglycan synthesisMtb-Selective 5‑Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities
Boshoff H, Young K, Ahn Y, Yadav V, Crowley B, Yang L, Su J, Oh S, Arora K, Andrews J, Manikkam M, Sutphin M, Smith A, Weiner D, Piazza M, Fleegle J, Gomez F, Dayao E, Prideaux B, Zimmerman M, Kaya F, Sarathy J, Tan V, Via L, Tschirret-Guth R, Lenaerts A, Robertson G, Dartois V, Olsen D, Barry C. Mtb-Selective 5‑Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities. ACS Infectious Diseases 2024, 10: 1679-1695. PMID: 38581700, DOI: 10.1021/acsinfecdis.4c00025.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntitubercular AgentsDrug Resistance, BacterialHumansLinezolidMiceMicrobial Sensitivity TestsMitochondriaMycobacterium tuberculosisOxazolidinonesProdrugsConceptsLinezolid-resistant mutantsDrug-resistant patientsAntitubercular activityN-acetyl metaboliteOxazolidinone prodrugMechanism of actionC3HeB/FeJ miceAntimycobacterial activityN-acetyl transferaseSusceptible to inhibitionCross-resistanceOxazolidinoneCompoundsMoleculesMammalian metabolismN-acetyltransferaseProdrugToxicityMoietyProtein synthesisLinezolidC3HeB/FeJCaseumPatientsLiving cells
2023
Tradeoffs in bacterial physiology determine the efficiency of antibiotic killing
Bren A, Glass D, Kohanim Y, Mayo A, Alon U. Tradeoffs in bacterial physiology determine the efficiency of antibiotic killing. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2312651120. PMID: 38096408, PMCID: PMC10742385, DOI: 10.1073/pnas.2312651120.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBacteriaBacterial Physiological PhenomenaMicrobial Sensitivity TestsModels, TheoreticalConceptsMinimal inhibitory concentrationBacterial physiologyCyclic adenosine monophosphateImprove antibiotic efficacyGrowth rateHigh-throughput assayEnvironmental conditionsRNA-seqAntibiotic killingAntibiotic actionBacterial deathAntibiotic efficacyInhibitory concentrationAntibiotic effectBactericidal activityGrowth conditionsCyclic adenosine monophosphate levelsAdenosine monophosphatePhysiological propertiesPhysiologyGrowthNonstress environmentsAssayDeathAntibioticsThe Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the United States
Yaesoubi R, Xi Q, Hsu K, Gift T, St. Cyr S, Rönn M, Salomon J, Grad Y. The Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the United States. American Journal Of Epidemiology 2023, 193: 17-25. PMID: 37625444, PMCID: PMC10773484, DOI: 10.1093/aje/kwad175.Peer-Reviewed Original ResearchConceptsRapid drug susceptibility testDrug susceptibility testGonorrhea casesSusceptibility testsFirst-line treatmentBurden of gonorrheaGonococcal infectionGonorrhoea transmissionAntibiotic treatmentPatient outcomesIndividualized treatmentLife spanDrug susceptibilityCare testRapid pointEffective life spanAntibiotic resistanceAntibioticsTest specificityGonorrheaMenCiprofloxacinTreatmentCorrect ascertainmentLong-term impactFighting the hidden pandemic of antimicrobial resistance in paediatrics: recommendations from the International Pediatric Association
Pana Z, El-Shabrawi M, Sultan M, Murray T, Alam A, Yewale V, Dharmapalan D, Klein J, Haddad J, Thacker N, Pulungan A, Hadjipanayis A. Fighting the hidden pandemic of antimicrobial resistance in paediatrics: recommendations from the International Pediatric Association. BMJ Paediatrics Open 2023, 7: e002084. PMID: 37500294, PMCID: PMC10387713, DOI: 10.1136/bmjpo-2023-002084.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsChildDrug Resistance, BacterialHumansMicrobial Sensitivity TestsPandemicsOpen-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease
Siegel S, Griffith D, Philley J, Brown-Elliott B, Brunton A, Sullivan P, Fuss C, Strnad L, Wallace R, Winthrop K. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease. CHEST Journal 2023, 164: 846-859. PMID: 37419144, PMCID: PMC10645596, DOI: 10.1016/j.chest.2023.05.036.Peer-Reviewed Original ResearchConceptsAmikacin liposome inhalation suspensionAmikacin resistanceCulture conversionInhalation suspensionMycobacterium abscessus lung diseasePresence of macrolide resistanceEnd pointsMicrobiological end pointsMonthly sputum culturesSputum culture conversionTreatment-refractory diseaseOpen-label protocolSecondary end pointsOpen-label trialCohort of patientsCavitary diseaseSputum culturePretreatment isolatesM abscessusOpen-labelOral antimicrobialsParenteral antibioticsCompanion therapyMacrolide resistanceMultidrug therapyMycobacterium tuberculosis Gene Expression Associated With Fluoroquinolone Resistance and Efflux Pump Inhibition
van der Heijden Y, Maruri F, Blackman A, Morrison R, Guo Y, Sterling T. Mycobacterium tuberculosis Gene Expression Associated With Fluoroquinolone Resistance and Efflux Pump Inhibition. The Journal Of Infectious Diseases 2023, 228: 469-478. PMID: 37079382, PMCID: PMC10428193, DOI: 10.1093/infdis/jiad112.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDrug Resistance, BacterialFluoroquinolonesGene ExpressionMicrobial Sensitivity TestsMycobacterium tuberculosisOfloxacinVerapamilConceptsExpression quantitative trait lociExpression quantitative trait loci analysisOfloxacin minimum inhibitory concentrationMinimum inhibitory concentrationWhole-genome sequencingRNA-seqEfflux pump inhibitionMTB isolatesGene expressionAllele frequency differencesQuantitative trait lociFluoroquinolone resistanceFold changePump inhibitionGenome sequenceFluoroquinolone-resistant Mycobacterium tuberculosisTrait lociRegulated genesAntituberculosis drug resistanceRNA sequencingEfflux pumpsEfflux pump inhibitor verapamilIncreased gene expressionGenesInhibitory concentration
2022
Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova
Cates L, Codreanu A, Ciobanu N, Fosburgh H, Allender C, Centner H, Engelthaler D, Crudu V, Cohen T, Menzies N. Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova. The International Journal Of Tuberculosis And Lung Disease 2022, 26: 963-969. PMID: 36163669, DOI: 10.5588/ijtld.22.0104.Peer-Reviewed Original ResearchMeSH KeywordsDrug ResistanceHigh-Throughput Nucleotide SequencingHumansMicrobial Sensitivity TestsMoldovaMycobacterium tuberculosisTuberculosis, Multidrug-ResistantConceptsPhenotypic drug susceptibility testingConventional phenotypic drug susceptibility testingTB drug resistanceDrug resistanceNext-generation sequencingTB treatment regimensNational TB ProgrammeDrug resistance testingMTB/RIFDrug susceptibility testingBudget impact analysisMajority of costsFeasibility of NGSTB programsTreatment regimensBudget impactSusceptibility testingRoutine useResistance testingStudy periodTesting volumeAntimicrobial resistance trends among canine Escherichia coli isolated at a New York veterinary diagnostic laboratory between 2007 and 2020
Osman M, Albarracin B, Altier C, Gröhn Y, Cazer C. Antimicrobial resistance trends among canine Escherichia coli isolated at a New York veterinary diagnostic laboratory between 2007 and 2020. Preventive Veterinary Medicine 2022, 208: 105767. PMID: 36181749, PMCID: PMC9703301, DOI: 10.1016/j.prevetmed.2022.105767.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Bacterial AgentsAnti-Infective AgentsCephalosporinsDog DiseasesDogsDrug Resistance, BacterialEnrofloxacinEscherichia coliEscherichia coli InfectionsFluoroquinolonesGentamicinsMicrobial Sensitivity TestsNew YorkRetrospective StudiesTrimethoprim, Sulfamethoxazole Drug CombinationConceptsTrimethoprim-sulfamethoxazole resistanceBody sitesGood first-line choiceCanine urinary tract infectionsResistant isolatesResistance trendsLaboratory Standards Institute breakpointsMultivariable logistic regression modelAntimicrobial resistance surveillance studyUrinary tract infectionDrug-resistant Escherichia coliFirst-line choiceAvailable clinical dataDrug-resistant E. coliAntimicrobial susceptibility patternsRetrospective study designUse of fluoroquinolonesE. coli infectionAntimicrobial resistance trendsResistance surveillance studiesClinical E. coliLogistic regression modelsEnrofloxacin-resistant isolatesSurvival analysis dataMIC trendsHigh rates of macrolide and fluoroquinolone resistance in human campylobacteriosis in the Middle East and North Africa
Dabbousi A, Osman M, Dabboussi F, Hamze M. High rates of macrolide and fluoroquinolone resistance in human campylobacteriosis in the Middle East and North Africa. Future Microbiology 2022, 17: 957-967. PMID: 35796073, DOI: 10.2217/fmb-2021-0302.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsCampylobacter InfectionsCampylobacter jejuniDrug Resistance, BacterialFluoroquinolonesHumansIntraabdominal InfectionsLebanonMacrolidesMicrobial Sensitivity TestsConceptsHuman campylobacteriosisRoutine stool cultureBacterial gastrointestinal infectionsClinical laboratoriesIncidence of campylobacteriosisPaucity of dataMain causative agentStool culturesGastrointestinal infectionsDiarrheal patientsMicrobiological diagnosisClinical importanceFluoroquinolone resistanceInfection prevalenceAntimicrobial resistanceZoonotic diseaseCausative agentCampylobacteriosisHigh rateAlarming ratePatientsCritical needEpidemiologyInfectionPrevalenceAn Optimized Electroporation Procedure for Genetic Transformation of Candida auris
Kasir D, Osman M, Hamze M, Bouchara J, Courdavault V, Papon N. An Optimized Electroporation Procedure for Genetic Transformation of Candida auris. Methods In Molecular Biology 2022, 2517: 89-94. PMID: 35674947, DOI: 10.1007/978-1-0716-2417-3_7.Peer-Reviewed Original ResearchMeSH KeywordsAntifungal AgentsCandidaCandida aurisDisease OutbreaksElectroporationHumansMicrobial Sensitivity TestsTransformation, GeneticLetter to the Editor: First Report of the Detection of the Plasmid-Borne Colistin Resistance Gene, mcr-1.26, in Multidrug-Resistant Escherichia coli Isolated from a Domesticated Pigeon
Kassem I, Assi A, Osman M, Mann D, Li S, Deng X. Letter to the Editor: First Report of the Detection of the Plasmid-Borne Colistin Resistance Gene, mcr-1.26, in Multidrug-Resistant Escherichia coli Isolated from a Domesticated Pigeon. Microbial Drug Resistance 2022, 28: 821-823. PMID: 35639443, DOI: 10.1089/mdr.2021.0359.Peer-Reviewed Original ResearchMachine-learning approaches prevent post-treatment resistance-gaining bacterial recurrences
Osman M, Mahieu R, Eveillard M. Machine-learning approaches prevent post-treatment resistance-gaining bacterial recurrences. Trends In Microbiology 2022, 30: 612-614. PMID: 35599112, DOI: 10.1016/j.tim.2022.05.006.Peer-Reviewed Original ResearchAnti-Bacterial AgentsBacteriaDrug Resistance, BacterialGenome, BacterialHumansMachine LearningMicrobial Sensitivity TestsRecurrenceA crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates
Fowler P, Wright C, Spiers H, Zhu T, Baeten E, Hoosdally S, Cruz A, Roohi A, Kouchaki S, Walker T, Peto T, Miller G, Lintott C, Clifton D, Crook D, Walker A, Barilar I, Battaglia S, Borroni E, Brandao A, Brankin A, Cabibbe A, Carter J, Cirillo D, Claxton P, Clifton D, Cohen T, Coronel J, Crook D, Earle S, Escuyer V, Ferrazoli L, Fowler P, Gao G, Gardy J, Gharbia S, Ghisi K, Ghodousi A, Cruz A, Grazian C, Guthrie J, He W, Hoffmann H, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Jarrett L, Joseph L, Jou R, Kambli P, Knaggs J, Koch A, Kohlerschmidt D, Kouchaki S, Lachapelle A, Lalvani A, Lapierre S, Laurenson I, Letcher B, Lin W, Liu C, Liu D, Malone K, Mandal A, Matias D, Meintjes G, Mendes F, Merker M, Mihalic M, Millard J, Miotto P, Mistry N, Moore D, Dreyer V, Chetty D, Musser K, Ngcamu D, Nhung H, Grandjean L, Nilgiriwala K, Nimmo C, Okozi N, Oliveira R, Omar S, Paton N, Peto T, Pinhata J, Plesnik S, Puyen Z, Rabodoarivelo M, Rakotosamimanana N, Rancoita P, Rathod P, Robinson E, Rodger G, Rodrigues C, Rodwell T, Roohi A, Santos-Lazaro D, Shah S, Kohl T, Smith G, Solano W, Spitaleri A, Supply P, Steyn A, Surve U, Tahseen S, Thuong N, Thwaites G, Todt K, Trovato A, Utpatel C, Van Rie A, Vijay S, Walker T, Walker A, Warren R, Werngren J, Groenheit R, Wijkander M, Wilkinson R, Wilson D, Wintringer P, Xiao Y, Yang Y, Yanlin Z, Yao S, Zhu B, Niemann S, O'Donnell M. A crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates. ELife 2022, 11: e75046. PMID: 35588296, PMCID: PMC9286738, DOI: 10.7554/elife.75046.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsHumansMicrobial Sensitivity TestsMycobacterium tuberculosisTuberculosisVolunteersConceptsMinimum inhibitory concentrationIncreasing prevalence of resistanceBroth microdilution platesAntibiotic susceptibility testingPrevalence of resistanceInhibitory concentrationPanel of antibioticsClinical samplesSusceptibility testingMicrodilution platesDilution platingTreatment outcomesIncreased prevalenceAntitubercular drugsAntibioticsInhibited growthDrugCitizen science platformRespiratory diseaseLaboratory scientistsVolunteersPre-determined concentrations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply